Amadix secured money through The Crowd Angel, in a round totalling €3.2M.

Amadix, a Valladolid, Spain-based biotech company, announced that it completed a a €1.2 million investment round added to the books of the company.

The funding was raised via an equity crowdfunding campaign on The Crowd Angel. The additional resources will go to the validation of the product, which will be evaluated by the United States Medicines Agency (FDA) and the European Medicines Agency (EMA).

The money is part of a larger round totalling €3.4 million and secured from investment networks Alentia, Sodica and the venture capital entities (venture capital) Inveready and CRB Inverbío.